The development of a human papillomavirus vaccine has received a lot of recent attentiondue to the connection between HPV infections and cervical cancer. One promising vaccine to prevent HPV infections is an HPV virus-like particle, and various studies have already shown that HPV VLP immunization elicits a humoral immune response. However, cell mediated immunity is important for the prevention of HPV infections and cancer therapy. Therefore, to check the elicitation of a CTL response by yeast-derived virus- like particles consisting of the HPV16 capsid protein L1, HPV16 L1 VLPs were produced and purified, then C57BL/6 mice immunized with the HPV16 L1 VLPs by subcutaneous injection. Thereafter, the splenocytes from the immunized mice were isolated and a chromium release assay performed using recombinant B16/HPV16 L1cells constantly expressing the HPV16 L1 protein. As a result, the data demonstrated that the T cells from the HPV16 L1 VLP immunized mice exhibited a significantly higher cytotoxic T lymphocyte activity against the recombinant B16/HPV16 L1 cells than the T cells from the PBS immunized control mice.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.